This inventor holds 0 USPTO granted patents, plus 1 CIPO patent.
Title: Anna Cederholm: Innovator in Atherothrombosis Research
Introduction
Anna Cederholm is a notable inventor based in Sweden, recognized for her contributions to the field of atherothrombosis research. Her work focuses on the mechanisms that lead to the rupture of atherosclerotic plaques, which is a significant factor in cardiovascular diseases. Cederholm's innovative approach has the potential to improve therapeutic strategies for preventing atherothrombosis.
Latest Patents
Cederholm holds a patent titled "Annexin V for Preventing Atherothrombosis and Plaque Rupture." This invention identifies factors that contribute to the decreased binding of Annexin V to the endothelium in patients with a history of atherothrombosis. The proposed use of native Annexin V or an N-terminal fragment, along with immunoglobulins, aims to enhance this binding and represents a novel mechanism for preventing atherothrombosis.
Career Highlights
Throughout her career, Anna Cederholm has worked with various organizations, including Annexin Pharmaceuticals AB. Her research has significantly advanced the understanding of atherothrombosis and its prevention. Despite having no patents attributed to her, her innovative ideas and research contributions are noteworthy.
Collaborations
Cederholm has collaborated with Johan Frostegard, a fellow researcher in the field. Their partnership has likely contributed to the development of new insights and advancements in atherothrombosis research.
Conclusion
Anna Cederholm is a pioneering inventor whose work in atherothrombosis research has the potential to transform therapeutic approaches. Her innovative ideas and collaborations continue to influence the field significantly.